144 related articles for article (PubMed ID: 38044594)
1. Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias.
Wesson W; Ahmed N; Rashid A; Tabak C; Logan E; Marchena-Burgos J; Nelson M; Davis JA; McGann M; Shune L; Hoffmann M; Abdallah AO; Hashmi H
Eur J Haematol; 2024 Apr; 112(4):538-546. PubMed ID: 38044594
[TBL] [Abstract][Full Text] [Related]
2. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
Zhou J; Zhang Y; Shan M; Zong X; Geng H; Li J; Chen G; Yu L; Xu Y; Li C; Wu D
Front Immunol; 2022; 13():997589. PubMed ID: 36131934
[TBL] [Abstract][Full Text] [Related]
3. Hematologic cytopenia post CAR T cell therapy: Etiology, potential mechanisms and perspective.
Si X; Gu T; Liu L; Huang Y; Han Y; Qian P; Huang H
Cancer Lett; 2022 Dec; 550():215920. PubMed ID: 36122628
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy.
Davis JA; Sborov DW; Wesson W; Julian K; Abdallah AO; McGuirk JP; Ahmed N; Hashmi H
Transplant Cell Ther; 2023 Sep; 29(9):567-571. PubMed ID: 37225044
[TBL] [Abstract][Full Text] [Related]
5. Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms.
Brudno JN; Natrakul D; Lam N; Dulau-Florea A; Yuan CM; Kochenderfer JN
Leuk Lymphoma; 2022 Aug; 63(8):1849-1860. PubMed ID: 35389319
[TBL] [Abstract][Full Text] [Related]
6. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
7. Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy.
Iqbal M; Bansal R; Yassine F; Gandhi S; Rosenthal A; Moustafa MA; Li Z; Craver EC; Mohty R; Murthy H; Ayala E; Tun H; Munoz J; Castro J; Lin Y; Kharfan-Dabaja MA
Transplant Cell Ther; 2022 Oct; 28(10):668.e1-668.e6. PubMed ID: 35842124
[TBL] [Abstract][Full Text] [Related]
8. Understanding the Etiology of Pancytopenias in the CAR T-Cell Therapy Setting: What We Know and What We Don't?
Yassine F; Murthy H; Ghabashi E; Kharfan-Dabaja MA; Iqbal M
Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):122-130. PubMed ID: 36633964
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor T-cell immunotherapies adverse events reported to FAERS database: focus on cytopenias.
Gomez-Lumbreras A; Mercadal Vilchez S; Villa-Zapata L; Malone DC; Couriel DR
Leuk Lymphoma; 2023 Dec; 64(13):2071-2080. PubMed ID: 37708442
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag for post-transplant cytopenias due to poor graft function.
Marotta S; Marano L; Ricci P; Cacace F; Frieri C; Simeone L; Trastulli F; Vitiello S; Cardano F; Pane F; Risitano AM
Bone Marrow Transplant; 2019 Aug; 54(8):1346-1353. PubMed ID: 30679824
[TBL] [Abstract][Full Text] [Related]
11. [The characteristics and impact on prognosis of cytopenia after anti-BCMA-CAR-T therapy in patients with relapsed and refractory multiple myeloma].
Shen XX; Yao Y; Xia Y; Jin YY; Zhang R; Li JY; Chen LJ
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):507-513. PubMed ID: 38317362
[No Abstract] [Full Text] [Related]
12. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors.
Xia Y; Zhang J; Li J; Zhang L; Li J; Fan L; Chen L
Ann Med; 2022 Dec; 54(1):2951-2965. PubMed ID: 36382675
[TBL] [Abstract][Full Text] [Related]
13. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity.
Jess J; Yates B; Dulau-Florea A; Parker K; Inglefield J; Lichtenstein D; Schischlik F; Ongkeko M; Wang Y; Shahani S; Cullinane A; Smith H; Kane E; Little L; Chen D; Fry TJ; Shalabi H; Wang HW; Satpathy A; Lozier J; Shah NN
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295816
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
15. The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma.
Jeong JY; Levine MS; Abayasekara N; Berliner N; Laubach J; Vanasse GJ
J Hematol Oncol; 2015 Apr; 8():37. PubMed ID: 25886818
[TBL] [Abstract][Full Text] [Related]
16. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells-single-center experience.
Beyar-Katz O; Perry C; On YB; Amit O; Gutwein O; Wolach O; Kedar R; Pikovsky O; Avivi I; Gold R; Ben-Ezra J; Shasha D; Ami RB; Ram R
Ann Hematol; 2022 Aug; 101(8):1769-1776. PubMed ID: 35731278
[TBL] [Abstract][Full Text] [Related]
19. Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party.
Penack O; Peczynski C; Koenecke C; Polge E; Kuhnl A; Fegueux N; Daskalakis M; Kröger N; Dreger P; Besley C; Schanz U; Bloor A; Ganser A; Forcade E; Corral LL; Passweg JR; Novak U; Moiseev I; Schoemans H; Basak GW; Chabannon C; Sureda A; Averbuch D; Glass B; de la Camara R; Peric Z
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072350
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
